Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis.
Alison R McCleanLucy ChengNick BansbackFiona ClementMina TadrousMark HarrisonMichael R LawPublished in: Arthritis care & research (2023)
We found that mandatory switching policies were much more effective than new starting policies for increasing the use of biosimilar medications.